5-Amino-1MQ for Health & Longevity - Quick Reference Sheet

5-Amino-1MQ for Health & Longevity

Created on 06/12/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A synthetic molecule that blocks an enzyme to support cellular energy and shift fat cells toward burning rather than storing fuel. In obese mice it lowered weight and fat and improved muscle repair, but no human studies exist — no proven dose, benefit, or safety record. Sold only as an unapproved research chemical of uncertain purity. (Full Review)

Protocol

Oral Capsule
50 mg/day
Once daily, often with food; sometimes up to 100 mg
Subcutaneous
150–500 mcg/day
Typically beginning at 150 mcg
Timing
Morning
Once-daily or split dosing; no validated standard
Time to effect
Metabolic & Body Composition
1–4 weeks
In obese mice; human timeline unknown

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Active or recent cancer, or cancer treatment
  • Significant liver disease
  • Inability to verify product identity and purity
Key Interactions
  • Diabetes and glucose-lowering medications
  • Drugs metabolized by methylation pathways
  • High-dose niacin or nicotinamide
  • NAD+ precursors (NMN, nicotinamide riboside)
  • Methyl donors (SAMe, betaine, methylfolate, methyl-B12)
  • Glucose-lowering supplements (berberine, alpha-lipoic acid)

Risk & Side Effects

  • High:
  • Medium:
  • Low:
  • Speculative: Unknown human safety profile; mild gastrointestinal and general symptoms; theoretical off-target methylation effects; product quality and contamination risk; use in vulnerable or cancer populations

Monitoring

Marker Target Why
Fasting glucose 75–90 mg/dL Tracks proposed glucose-lowering effect
Fasting insulin 2–5 µIU/mL Detects insulin-sensitivity changes
HbA1c <5.4% Longer-term glucose control
ALT / AST ALT <25 U/L; AST <25 U/L Liver is a target tissue; watch for stress
Lipid panel (total/LDL/HDL/triglycerides) Triglycerides <80 mg/dL; HDL >50 mg/dL Mouse data showed cholesterol reduction
Homocysteine <8 µmol/L Mechanistic concern from SAH/homocysteine pathway

Cadence: Baseline, then around 4–8 weeks, then every 3–6 months

Qualitative Assessment

  • Energy levels and daytime fatigue
  • Body composition and waist circumference changes
  • Exercise recovery and perceived muscle soreness
  • General well-being and appetite